Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 31680063 | HLA-C (HLA-C) | recurrent miscarriage | NA | NA | NA | positive+negation | |
| administration of g-csf at embryo transfer and during early pregnancy in recurrent miscarriage patients with kir-hla-c mismatch undergoing egg donation art treatment does not convey a higher risk of perinatal complications. | |||||||
| 12742663 | MHC (MHC) | inflammatory myopathies | NA | NA | NA | unclassified | |
| antigen processing and presentation in human muscle: cathepsin s is critical for mhc class ii expression and upregulated in inflammatory myopathies. | |||||||
| 12742663 | MHC (MHC) | inflammatory myopathies | NA | NA | NA | unclassified | |
| to further elucidate the molecular basis for the mhc class ii-mediated antigen presentation by muscle cells, we here analyzed cultured human myoblasts and biopsies from inflammatory myopathies with respect to the expression and function of the constituents of the mhc class ii antigen presentation machinery. | |||||||
| 12742663 | HLA-DR (HLA-DR) | inflammatory myopathies | NA | NA | NA | unclassified | |
| we identified cathepsin s (cats) as the dominant endocytic protease that is specifically upregulated under inflammatory conditions to significant mrna levels, synchronously with hla-dr, -dm and the class ii invariant chain (ii), both in muscle biopsies from affected individuals with inflammatory myopathies and in human myoblasts cultured in the presence of ifn-gamma. | |||||||
| 12218775 | HLA-CLASS I (HLA CLASS II) | viral disease | NA | NA | NA | unclassified | |
| epitope-specific cd8(+)t cell responses to malignant and viral disease can be accurately measured using tetramers (thla) of hla class i molecules loaded with antigenic peptides. | |||||||
| 32303592 | HLA (HLA) | viral disease | NA | NA | NA | unclassified | |
| pairing hla typing with covid-19 testing where feasible could improve assessment of severity of viral disease in the population. | |||||||
| 32303592 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | severe acute respiratory syndrome | NA | NA | NA | unclassified | |
| human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2. | |||||||
| 32303592 | HLA-A (HLA-A) | severe acute respiratory syndrome | NA | NA | NA | unclassified | |
| genetic variability across the three major histocompatibility complex (mhc) class i genes (human leukocyte antigen a [hla-a], -b, and -c genes) may affect susceptibility to and severity of the disease caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2), the virus responsible for coronavirus disease 2019 (covid-19). | |||||||
| 19036163 | MHC (MHC) | immunological disease | NA | epitopic | NA | positive | |
| the observed relationship between peptide length and mhc class ii affinity has significant implications for the design of vaccines and the study of the epitopic basis of immunological disease. | |||||||
| 8437594 | HLA (HLA) | glycogen storage disease | NA | NA | NA | negation | |
| immunocytochemical analysis showed cells containing the hla phenotypes of the donor in the heart and skin of the patients with glycogen storage disease and in the lymph nodes, but not the skin, of the patient with gaucher's disease. | |||||||
Copyright 2024